418 ENDOGLIN-RELATED PATHWAYS ARE NOT RELATED TO DISTINCT PREDISPOSITION TO ATHEROSCLEROSIS IN C57BL/6J AND C3H/HEJ MICE von Rathouska, J., Strasky, Z., Vecerova, L., Brcakova, E., Slanarova, M., Nachtigal, P.

Volltext

409 CHANGES OF ENDOGLIN LEVELS IN SERUM AND MICE AORTA WITH RESPECT TO CHOLESTEROL AND ATORVASTATIN von Večeřová, L., Strasky, Z., Rathouska, J., Slanarova, M., Brcakova, E., Nachtigal, P.

Volltext

95 ATORVASTATIN INCREASES CHOLESTEROL LEVELS IN APOE/LDLR-DEFICIENT MICE von Slanarova, M., Brcakova, E., Vecerova, L., Strasky, Z., Rathouska, J., Hyspler, R., Ticha, A., Nachtigal, P.

Volltext

P424 ENDOGLIN (TYPE III TGF-β1 RECEPTOR), BAD OR GOOD IN ATHEROSCLEROSIS? von Nachtigal, P., Strasky, Z., Vecerova, L., Brcakova, E., Slanarova, M., Rathouska, J., Micuda, S.

Volltext

P407 ENDOGLIN EXPRESSION IN ATHEROGENESIS IS NOT RELATED TO EITHER CHOLESTEROL LEVELS OR PLAQUE SIZE IN ApoE/LDLR DOUBLE KNOCKOUT MICE von Vecerova, L., Strasky, Z., Rathouska, J., Slanarova, M., Brcakova, E., Micuda, S., Nachtigal, P.

Volltext

P412 PLEIOTROPIC EFFECTS OF ATORVASTATIN AND TGF-β/ENDOGLIN CASCADE IN THE VESSEL WALL OF ApoE/LDLR DOUBLE KNOCKOUT MICE von Strasky, Z., Vecerova, L., Slanarova, M., Rathouska, J., Brcakova, E., Micuda, S., Nachtigal, P.

Volltext

MS38 ATORVASTATIN EFFECTS ON LIPID PROFILE IN ApoE/LDLR-DEFICIENT MICE von Slanařová, M., Večeřová, L., Stráský, Z., Tichá, A., Hyšpler, R., Nachtigal, P.

Volltext

Developing Nanostructured Ti Alloys for Innovative Implantable Medical Devices von Valiev, Ruslan Z, Prokofiev, Egor A, Kazarinov, Nikita A, Raab, Georgy I, Minasov, Timur B, Stráský, Josef

Volltext